Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
298.49(c) 295.54(c) 289.32(c) 293.2(c) 291.71(c) Last
931 996 738 111 1 420 160 919 368 813 435 Volume
-0.57% -0.99% -2.10% +1.34% -0.51% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 10 782 M - -
Net income 2021 1 957 M - -
Net Debt 2021 1 558 M - -
P/E ratio 2021 22,4x
Yield 2021 -
Sales 2022 11 242 M - -
Net income 2022 2 694 M - -
Net cash position 2022 1 480 M - -
P/E ratio 2022 17,0x
Yield 2022 -
Capitalization 43 475 M 43 475 M -
EV / Sales 2021 4,18x
EV / Sales 2022 3,74x
Nbr of Employees 9 100
Free-Float 84,9%
More Financials
Company
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Ratings of Biogen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BIOGEN INC.
09/23BIOGEN : Issues First Progress Report of its Signature Healthy Climate, Healthy Lives&trad..
PU
09/23BIOGEN : Needham Starts Biogen at Buy With $400 Price Target
MT
09/22VC DAILY : Indian Ed-Tech Startup Boosts U.S. Expansion With Summer Deals
DJ
09/21BIOGEN : FDA Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (ra..
AQ
09/21BIOGEN : 2021 Investor R&D Day
PU
09/21BIOGEN : R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potenti..
AQ
09/20BIOGEN : MS Portfolio
PU
09/20BIOGEN : Gene Therapy
PU
09/20BIOGEN : Biomarkers
PU
09/20BIOGEN : Biotherapeutics and Medicinal Sciences at Biogen
PU
09/20BIOGEN : Human Genetics
PU
09/20BIOGEN : Movement Disorders at Biogen
PU
09/20BIOGEN : Digital Health
PU
09/20BIOGEN : Advancements in Research
PU
09/20BIOGEN : Alzheimer's Disease Research Portfolio
PU
More news
News in other languages on BIOGEN INC.
09/21Apple will iPhones zur Erkennung von Depressionen einsetzen - Kreise
09/20Byooviz de Biogen et Samsung Bioepis approuvé par la FDA
09/19ALZHEIMER : un nouvel espoir, timide, pour traiter la maladie
09/19Alzheimer, la démence la plus connue
09/17L'Agence européenne des médicaments recommande la mise sur le marché de Vumerity de Bio..
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 291,71 $
Average target price 417,77 $
Spread / Average Target 43,2%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors